Persy

Persy’s August 2026 category mix pivoted toward higher-velocity inhalables while the legacy Capsules base contracted in-month: Capsules held 50.70% share with a 93.60% year-over-year gain but a 9.75% month-over-month decline, Concentrates rose to 35.73% share with 190.63% year-over-year growth and an 80.85% month-over-month surge, and Vapor Pens climbed to 12.25% share with 605.30% year-over-year growth and 63.69% month-over-month growth. Pre-Roll slipped to 1.33% share with a 45.14% month-over-month drop and no year-over-year comparable. The mix indicates Persy is rapidly diversifying away from a Capsules-centric profile toward inhalable formats; despite a 13.46% year-over-year average price increase and a 55.63% brand-level sales lift, the month’s negative move in Capsules combined with outsized month-over-month gains in Concentrates and Vapor Pens implies near-term volume is migrating to higher-priced, faster-expanding segments.

Positioning-wise, the shift concentrates Persy’s growth engine in higher-ticket inhalables, which can sustain premium pricing as Concentrates average $63.20 and Vapor Pens average $35.85 while Capsules average $26.78; with Concentrates up 80.85% month-over-month and Vapor Pens up 63.69% month-over-month, Persy’s exposure to volatile but scalable formats increases as Capsules’ 9.75% month-over-month decline reduces reliance on a lower-priced anchor. In Ontario Capsules, Persy sits at rank 16, and with Capsules still at 50.70% share versus inhalables at a combined 47.98%, the brand is at an inflection where incremental share gains in Concentrates and Vapor Pens could offset rank constraints in Capsules; the pattern signals that reallocating assortment and marketing toward inhalables can compound the 114.98% two-year sales expansion while cushioning against month-specific Capsules softness.